within Pharmacolibrary.Drugs.ATC.D;

model D05AD01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.3333333333333333,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Trioxysalen (trimethylpsoralen, TMP) is a furocoumarin used mainly as a photosensitizing agent in PUVA (psoralen and ultraviolet A) therapy for the treatment of vitiligo, psoriasis, and other skin disorders. It is not widely used today due to the availability of newer agents and concerns about long-term risks such as skin cancer.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models with explicit numeric parameters for trioxysalen could be found in major sources. The parameters below are rough estimates derived from related psoralen drugs and limited pharmacokinetic mention in secondary literature. Estimated for healthy adult oral administration.</p><h4>References</h4><ol><li><p>de Wolff, FA, &amp; Thomas, TV (1986). Clinical pharmacokinetics of methoxsalen and other psoralens. <i>Clinical pharmacokinetics</i> 11(1) 62–75. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198611010-00004&quot;>10.2165/00003088-198611010-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3512141/&quot;>https://pubmed.ncbi.nlm.nih.gov/3512141</a></p></li><li><p>Shephard, SE, &amp; Panizzon, RG (1999). Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy. <i>Dermatology (Basel, Switzerland)</i> 199(2) 106–112. DOI:<a href=&quot;https://doi.org/10.1159/000018215&quot;>10.1159/000018215</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10559574/&quot;>https://pubmed.ncbi.nlm.nih.gov/10559574</a></p></li><li><p>Pathak, MA, et al., &amp; Rodighiero, G (1983). A study of the relationship between photosensitizing and therapeutic activity of 4,5&#x27;,8-trimethylpsoralen, and its major metabolite 4,8-dimethyl, 5&#x27;-carboxypsoralen. <i>The Journal of investigative dermatology</i> 81(6) 533–539. DOI:<a href=&quot;https://doi.org/10.1111/1523-1747.ep12522886&quot;>10.1111/1523-1747.ep12522886</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6644095/&quot;>https://pubmed.ncbi.nlm.nih.gov/6644095</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D05AD01;
